GLP-1 Access Debate: Brazil Obesity Surge Spurs Democratization Push

The article discusses the rapid impact of GLP-1 agonists (weight loss pens) and the challenge of democratizing access, highlighting Brazil's obesity rate surge from 11.8% (2016) to 25.7% (2024). The piece is subscriber-only, so full details on policy or market implications are unavailable. It signals a growing public-health and affordability debate around these drugs.